Abstract
The phase II study aimed to evaluate the safety and efficacy of non-invasive infrared polarized light device on patients with chronic migraine (CM). Forty patients aged between 18 and 60 years with a diagnosis of CM were included. Sociodemographic and clinical information were obtained by face-to-face interviews with the patients and they had migraine diary containing headache information before and monthly during 4 months of the treatment. Clinical data included age of migraine onset, duration of disease as years, total headache days per month, severity of headache assessed by visual analogue scale (VAS), number of painkillers used monthly, and impact of headache on patients' home, work and social life activities. Short form-36 (SF-36) was used to examine for the quality of life. Migraine therapy devices; both active and inactive, were given to the patients to use at home according to study protocol, double-blinded, randomized, sham-controlled trial. Statistical analysis was performed using the SAS University Edition 9.4 program. A total of 40 patients, 36 (90%) were female and t he mean age was 37.50 ± 9.77 years . The mean duration of migraine was 12.74 ± 9.55 years. Migraine therapy device was well tolerated without any side effects.
Get full access to this article
View all access options for this article.